Which combination is considered problematic due to QT prolongation risk when used together with SSRI therapy?

Which combination is considered problematic due to QT prolongation risk when used together with SSRI therapy?

• A. Tricyclic antidepressants and antipsychotics
• B. Selective Serotonin Reuptake Inhibitors and Benzodiazepines
• C. Mirtazapine and Bupropion
• D. SSRIs and Beta-blockers

Answer: (A)

Prolongation of the QT interval becomes especially risky when multiple drugs that affect cardiac repolarization are used together. Tricyclic antidepressants and antipsychotics each have the potential to prolong the QT interval by blocking the heart’s potassium channels (hERG), which slows repolarization and lengthens the QT. When these agents are used in combination with SSRI therapy, the overall effect on the heart’s electrical timing can be additive, increasing the chance of dangerous arrhythmias such as torsades de pointes, particularly in patients who have electrolyte abnormalities, are female, or are at higher baseline risk. Other pairings listed don’t carry the same QT risk generally. SSRIs with benzodiazepines don’t typically affect the QT interval. Mirtazapine and bupropion don’t have a significant QT prolongation concern when used together with SSRIs. SSRIs with beta-blockers also don’t meaningfully prolong the QT. The key idea is that combining multiple QT-prolonging medications, such as a TCA and an antipsychotic, with SSRI therapy, poses the greatest risk.

Prolongation of the QT interval becomes especially risky when multiple drugs that affect cardiac repolarization are used together. Tricyclic antidepressants and antipsychotics each have the potential to prolong the QT interval by blocking the heart’s potassium channels (hERG), which slows repolarization and lengthens the QT. When these agents are used in combination with SSRI therapy, the overall effect on the heart’s electrical timing can be additive, increasing the chance of dangerous arrhythmias such as torsades de pointes, particularly in patients who have electrolyte abnormalities, are female, or are at higher baseline risk.

Other pairings listed don’t carry the same QT risk generally. SSRIs with benzodiazepines don’t typically affect the QT interval. Mirtazapine and bupropion don’t have a significant QT prolongation concern when used together with SSRIs. SSRIs with beta-blockers also don’t meaningfully prolong the QT. The key idea is that combining multiple QT-prolonging medications, such as a TCA and an antipsychotic, with SSRI therapy, poses the greatest risk.